Vertex – “Testing Time Ahead for INCIVEK - After 2013!”
INCIVEK (Telaprevir, L, HCV) should sustain its momentum till FY13 and only successful launch of Gilead/VRUS’s and others IFN-free drugs in 2014, would result in declining sales for INCIVEK/IFN combination. Vertex (VRTX) next target is to capture the HCV/HIV co-infected patients and gain greater HCV market through shorter duration and dosing advantage to a niche pts population of IL28B CC Genotype. Down side risk are hedged due to pipeline drugs targeting Rheumatoid Arthritis (RA), Cystic Fibrosis (CF), etc. For more details, please read our report released on 25th November, 2011 on VRTX titled “Testing Time Ahead for INCIVEK - After 2013!”
COMPANIES MENTIONED
Vertex
Vertex
